MTST (MetaStat) Forward Dividend Yield %: 0.00% (As of Jun. 27, 2026)


What is MetaStat Forward Dividend Yield %?

MetaStat MTST Forward Dividend Yield % is 0.00% as of Jun. 27, 2026.

As of today (2026-06-27), the Forward Annual Dividend Yield of MetaStat is 0.00%.

As of today (2026-06-27), the Trailing Annual Dividend Yield of MetaStat is 0.00%.

MTST's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.525
* Ranked among companies with meaningful Forward Dividend Yield % only.

MetaStat's Dividends per Share for the three months ended in Feb. 2018 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

MetaStat  (OTCPK:MTST) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

MetaStat Forward Dividend Yield % Related Terms

MTST vs OBMP, NSPX, ATRX: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, MetaStat's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MetaStat Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MetaStat's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where MetaStat's Forward Dividend Yield % falls into.


MetaStat Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
MetaStat (MTST) has a Forward Dividend Yield % of 0.00% as of Jun. 27, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on MetaStat and its competitors.
Is MetaStat's Forward Dividend Yield % too high?
MetaStat's current Forward Dividend Yield % is 0.00%.
How does MetaStat's Forward Dividend Yield % compare to OBMP and NSPX?
MetaStat's Forward Dividend Yield % of 0.00% can be compared against companies in the Biotechnology industry. The industry median Forward Dividend Yield % is 1.53. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.53, based on 146 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on MetaStat and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MetaStat's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MetaStat stock overvalued right now?
MetaStat (MTST) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For MetaStat (MTST), the current Forward Dividend Yield % is 0.00% as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MetaStat Business Description

Address 27 Drydock Avenue, 2nd Floor, Boston, MA, USA, 02210
MetaStat Inc is a us-based biotechnology company which focuses on discovering and developing personalized therapeutic (Rx) and diagnostic (Dx) treatment solutions for cancer patients. The company focuses on development programs of the novel therapeutic product candidates that target the Mena protein isoform whereas the Companion Diagnostics program is focused on developing companion tests to be used in combination with cancer drugs, that provide essential information for the safe and effective use of a corresponding drug or biological product to improve patient outcome. It also develops a prognostic diagnostic program which is focused on developing diagnostic tests that predict the risk of future metastasis in cancer patients following the initial treatment of their primary tumor.